Brentuximab Vedotin Compared with Other Therapies in Relapsed/Refractory Hodgkin Lymphoma Post ASCT: Median Overall Survival Meta-Analysis

Curr Med Res Opin. 2015 May 7:1-48

This meta-analysis compared the median overall survival (mOS) of brentuximab vedotin reported in the pivotal phase 2 study with published results of other therapies for the treatment of relapsed/refractory (R/R) Hodgkin lymphoma (HL) post autologous stem cell transplant (ASCT).

View abstract


Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D